Beyond BRCA: Genetic testing for gynaecological cancers in South Africa
DOI:
https://doi.org/10.7196/SAMJ.2026.v116i2.3514Keywords:
gynaecological oncology, hereditary cancers, genetic counselling, hereditary breast and ovarian cancer (HBOC) , ovarian cancer, uterine cancer, Lynch syndromeAbstract
Background. Hereditary cancer syndromes, caused by pathogenic variants in specific genes, substantially increase an individual’s risk for cancer, and are estimated to cause 10% of all uterine cancers and 20% of all ovarian cancers. However, these data are primarily based on high-income countries, and to date there are no published data on the known pathogenic variants or testing of cancer predisposition genes associated with gynaecological cancers in South Africa.
Objectives. To investigate the uptake and type of molecular testing performed on patients with a suspected hereditary cancer syndrome associated with gynaecological cancer, and to assess whether patient characteristics impacted the detection of pathogenic variants.
Methods. A retrospective file review was performed for patients with a confirmed diagnosis or family history of gynaecological cancer, seen by a single clinical genetics centre in Johannesburg between 2003 and 2023. Demographic information, family history and medical information were recorded and analysed.
Results. A total of 104 records were included in analysis. The majority (73/104, 70.2%) of patients were seen in the private healthcare system, of whom most (41%) were of European ancestry. Of the remaining 31 public healthcare patients, the majority were of indigenous African ancestry (42%). Most (78/104, 75.0%) underwent diagnostic genetic testing. Of these, 25 (32.1%) were positive for pathogenic variants, 41 (52.6%) were negative and 12 (15.4%) returned a variant of unknown significance. Test results were significantly different between patients of European and non-European ancestry (p<0.05), with those of non-European ancestry 30% less likely to have a pathogenic variant detected (odds ratio 0.7, 95% confidence interval 0.22 - 2.21).
Conclusion. A disparity exists not only in genetic testing availability but also clinic attendance between the public and private healthcare systems, which likely limits the ability to diagnose hereditary cancer syndromes associated with gynaecological cancers in public healthcare hospitals.
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249. https://
doi.org/10.3322/caac.21660
2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer today. Lyon: International Agency
for Research on Cancer, 2020. https://gco.iarc.fr/today/about (accessed 2 January 2023).
3. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol 2020;40(5):602-608.
https://doi.org/10.1080/01443615.2019.1634030
4. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome
in young women with endometrial cancer. J Clin Oncol 2007;25(33):5158-5164. https://doi.
org/10.1200/JCO.2007.10.8597
5. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube,
and peritoneal carcinoma identified by massively parallel sequencing. Proc Nat Acad Sci
2011;108(44):18032-18037. https://doi.org/10.1073/pnas.1115052108
6. Walsh MF, Cadoo K, Salo-Mullen EE, Dubard-Gault M, Stadler ZK, Offit K. Genetic factors:
Hereditary cancer predisposition syndromes. In: Niederhuber JE, Kastan MB, Tepper JE, Armitage JO,
Doroshow JH, eds. Abeloff’s Clinical Oncology. 6th ed. Amsterdam: Elsevier, 2020:180-208. https://
www.sciencedirect.com/science/article/pii/B978032347674400013X (accessed 11 January 2023).
7. Toss A, Tomasello C, Razzaboni E, et al. Hereditary ovarian cancer: Not only BRCA 1 and 2 genes.
Biomed Res Int 2015;2015(1):341723. https://doi.org/10.1155/2015/341723
8. Beggs AD, Latchford AR, Vasen HFA, et al. Peutz-Jeghers syndrome: A systematic review and
recommendations for management. Gut 2010;59(7):975-986. https://doi.org/10.1136/gut.2009.198499
9. Kalra A, Sobocan M, Reisel D, Manchanda R. Role of genetics in gynaecological cancers. In: Singh K,
Gupta B, eds. Gynecological Oncology: Basic Principles and Clinical Practice. Cham: Springer
International Publishing, 2022:207-220. https://doi.org/10.1007/978-3-030-94110-9_17
10. American Cancer Society. Lifetime risk of developing or dying from cancer. Atlanta (GA): American
Cancer Society, 2025 (last revised 30 January 2025). https://www.cancer.org/cancer/risk-prevention/
understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html (accessed
2 January 2023).
11. Lynch JA, Venne V, Berse B. Genetic tests to identify risk for breast cancer. Semin Oncol Nurs
2015;31(2):100-107. https://doi.org/10.1016/j.soncn.2015.02.007
12. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:
A joint consensus recommendation of the American College of Medical Genetics and Genomics and
the Association for Molecular Pathology. Genetics Med 2015;17(5):405-424. https://doi.org/10.1038/
gim.2015.30
13. Mighton C, Shickh S, Uleryk E, Pechlivanoglou P, Bombard Y. Clinical and psychological outcomes of
receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: A
systematic review and meta-analysis. Genetics Med 2021;23(1):22-33. https://doi.org/10.1038/s41436-
020-00957-2
14. Daly MB, Pilarski R, Yurgelun MB, et al. NCCN guidelines insights: Genetic/familial high-risk
assessment: Breast, ovarian, and pancreatic, version 1.2020. J Nat Comprehensive Cancer Network
2020;18(4):380-391. https://doi.org/10.6004/jnccn.2020.0017
15. Gupta S, Provenzale D, Llor X, et al. NCCN guidelines insights: Genetic/familial high-risk assessment:
Colorectal, version 2.2019. J Nat Comprehensive Cancer Network 2019;17(9):1032-1041. https://doi.
org/10.6004/jnccn.2019.0044
16. Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients
receiving colonoscopic and gynaecological surveillance: First report from the prospective Lynch
syndrome database. Gut 2017;66(3):464-472. https://doi.org/10.1136/gutjnl-2015-309675
17. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses
in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28(15):2512-
2519. https://doi.org/10.1200/JCO.2009.26.9589
18. Hampel H. Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer
2016;15(3):423-427. https://doi.org/10.1007/s10689-016-9893-5
19. Schoeman M, Apffelstaedt JP, Baatjes K, Urban M. Implementation of a breast cancer genetic service in
South Africa – lessons learned. S Afr Med J 2013;103(8):529. https:// 10.7196/SAMJ.6814
20. Van der Merwe NC, Ntaita KS, Stofberg H, Combrink HMvE, Oosthuizen J, Kotze MJ. Implementation
of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in
oncology for the public sector. Front Oncol 2022;12:938561. https://doi.org/10.3389/fonc.2022.938561
21. Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D. The health and health system of South Africa:
Historical roots of current public health challenges. Lancet 2009;374(9692):817-834. https://doi.
org/10.1016/S0140-6736(09)60951-X
22. Gardiner SA, Smith D, Loubser F, Raimond P, Gerber J, Conradie M. New recurring BRCA1 variant:
An additional South African founder mutation? S Afr Med J 2019;109(8):544. https://doi.org/10.7196/
SAMJ.2019.v109i8.14187
23. Seymour HJ, Wainstein T, Macaulay S, Haw T, Krause A. Breast cancer in high-risk Afrikaner families:
Is BRCA founder mutation testing sufficient? S Afr Med J 2016;106(3):264. https://doi.org/10.7196/
SAMJ.2016.v106i3.10285
24. Gizaw M, Parkin DM, Stöter O, et al. Trends in the incidence of ovarian cancer in sub-Saharan Africa.
Int J Cancer 2022;152(7):1328-1336. https://doi.org/10.1002/ijc.34335
25. Landrum MJ, Lee JM, Benson M, et al. ClinVar: Improving access to variant interpretations and
supporting evidence. Nucleic Acids Res 2018;46(D1):D1062-1067. https://doi.org/10.1093/nar/gkx1153
26. Statistics South Africa. Statistical resease P0302. 2022. Mid-year population estimates, 2022. https://
www.statssa.gov.za/publications/P0302/P03022022.pdf (accessed 17 November 2023).
27. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM. Disparities in genetics assessment for
women with ovarian cancer: Can we do better? Gynecol Oncol 2018;149(1):84-88. https://doi.
org/10.1016/j.ygyno.2017.10.034
28. Nikolaidis C, Duquette D, Mendelsohn-Victor KE, et al. Disparities in genetic services utilisation in
a random sample of young breast cancer survivors. Genetics Med 2019;21(6):1363-1370. https://doi.
org/10.1038/s41436-018-0349-1
29. Van Wyk C, Wessels TM, Kromberg JGR, Krause A. Knowledge regarding basic concepts of hereditary
cancers, and the available genetic counselling and testing services: A survey of general practitioners in
Johannesburg, South Africa. S Afr Med J 2016;106(3):268. https:// 10.7196/SAMJ.2016.v106i3.10162
30. Tan Y, Fitzgerald L. Barriers and motivators for referral of patients with suspected Lynch syndrome
to cancer genetic services: A qualitative study. J Pers Med 2014;4(1):20-34. https://doi.org/10.3390/
jpm4010020
31. Pujol P, Lyonnet DS, Frebourg T, et al. Lack of referral for genetic counseling and testing in BRCA1/2
and Lynch syndromes: A nationwide study based on 240,134 consultations and 134,652 genetic tests.
Breast Cancer Res Treat 2013;141(1):135-144. https://doi.org/10.1007/s10549-013-2669-9
32. Düsterwald G. Understanding doctors’ knowledge and attitudes concerning genetics and genetic
services in South Africa. MSc thesis. Cape Town: University of Cape Town, 2015. https://hdl.handle.
net/11427/16487 (accessed 4 July 2025).
33. Swinny CA, Kagee A, Roomaney R. Delayed help-seeking for symptomatic breast cancer: Reasons for
delay among participants receiving treatment at a public healthcare facility in South Africa. S Afr J
Psychol 2022;52(1):87-98. https://doi.org/10.1177/0081246321992477
34. Uwayezu D, Ntigura E, Gatarayiha A, et al. Conflict between science and superstition in medical
practices. Int Med Educ 2022;1(2):33-42. https://doi.org/10.3390/ime1020007
35. Van der Hoeven M, Kruger A, Greeff M. Differences in health care seeking behaviour between
rural and urban communities in South Africa. Int J Equity Health 2012;11(1):31. https://doi.
org/10.1186/1475-9276-11-31
36. Gomes MCM, Gomes BJ, Christianson AL, Bailly C, McKerrow N, Malherbe HL. A capacity
audit of medical geneticists and genetic counsellors in South Africa, 2024: A national crisis. Genes
2024;15(9):1173. https://doi.org/10.3390/genes15091173
37. Velázquez C, Lastra E, Avila Cobos F, et al. A comprehensive custom panel evaluation for routine
hereditary cancer testing: Improving the yield of germline mutation detection. J Transl Med
2020;18(1):232. https://doi.org/10.1186/s12967-020-02391-z
38. Idos GE, Kurian AW, Ricker C, et al. Multicenter prospective cohort study of the diagnostic yield
and patient experience of multiplex gene panel testing for hereditary cancer risk. JCO Precis Oncol
2019;(3):1-12. https://doi.org/10.1200/PO.18.00217
39. Nanda R, Schumm LP, Cummings S, et al. Genetic testing in an ethnically diverse cohort of high-risk
women. JAMA 2005;294(15):1925. https://doi.org/10.1001/jama.294.15.1925
40. Makhnoon S, Levin B, Ensinger M, et al. A multicenter study of clinical impact of variant of uncertain
significance reclassification in breast, ovarian and colorectal cancer susceptibility genes. Cancer Med
2023;12(3):2875-2884. https://doi.org/10.1002/cam4.5202
41. Loong L, Garrett A, Allen S, et al. Reclassification of clinically-detected sequence variants: Framework
for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK).
Genetics Med 2022;24(9):1867-1877. https://doi.org/10.1016/j.gim.2022.05.002
42. Turnbull C, Sud A, Houlston RS. Cancer genetics, precision prevention and a call to action. Nat Genet
2018;50(9):1212-1218. https://doi.org/10.1038/s41588-018-0202-0
43. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast
cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc 2017;317(23):2402-2416. https://
doi.org/10.1001/jama.2017.7112
44. Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350
carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome
Database. Genetics Med 2020;22(1):15-25. https://doi.org/10.1038/s41436-019-0596-9
45. Van der Merwe N, Hamel N, Schneider SR, Apffelstaedt J, Wijnen J, Foulkes W. A founder BRCA2
mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. Clin Genet
2012;81(2):179-184. https://doi.org/10.1111/j.1399-0004.2010.01617.x
46. Krause A, Mitchell C, Essop F, et al. Junctophilin 3 (JPH3) expansion mutations causing Huntington
disease-like 2 (HDL2) are common in South African patients with African ancestry and a Huntington
disease phenotype. Am J Med Genetics Part B: Neuropsychiatric Genetics 2015;168(7):573-585.
https://doi.org/10.1002/ajmg.b.32332
47. Adedokun B, Zheng Y, Ndom P, et al. Prevalence of inherited mutations in breast cancer predisposition
genes among women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Preven 2020;29(2):359-
367. https://doi.org/10.1158/1055-9965.EPI-19-0506
48. Zheng Y, Walsh T, Gulsuner S, et al. Inherited breast cancer in Nigerian women. J Clin Oncol
2018;36(28):2820-2825. https://doi.org/10.1200/JCO.2018.78.3977
49. Eygelaar D, van Rensburg EJ, Joubert F. Germline sequence variants contributing to cancer
susceptibility in South African breast cancer patients of African ancestry. Sci Rep 2022;12(1):802.
https://doi.org/10.1038/s41598-022-04791-1
50. Manchanda R, Patel S, Antoniou AC, et al. Cost-effectiveness of population based BRCA testing with
varying Ashkenazi Jewish ancestry. Am J Obstet Gynecol 2017;217(5):578.e1-578.e12. https://doi.
org/10.1016/j.ajog.2017.06.038
51. Beard C, Monohan K, Cicciarelli L, James PA. Mainstream genetic testing for breast cancer patients:
Early experiences from the Parkville Familial Cancer Centre. Eur J Hum Genetics 2021;29(5):872-880.
https://doi.org/10.1038/s41431-021-00848-3
52. Kromberg JGR, Wessels T, Krause A. Roles of genetic counselors in South Africa. J Genet Couns
2013;22(6):753-761. https://doi.org/10.1007/s10897-013-9606-2
53. Kahn RM, Ahsan MD, Chapman-Davis E, et al. Barriers to completion of cascade genetic testing: How
can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome? Fam Cancer
2023;22(2):127-133. https://doi.org/10.1007/s10689-022-00316-x
54. Schmidlen TJ, Bristow SL, Hatchell KE, Esplin ED, Nussbaum RL, Haverfield EV. The impact of
proband indication for genetic testing on the uptake of cascade testing among relatives. Front Genet
2022;13:867226. https://doi.org/10.3389/fgene.2022.867226
55. Courtney E, Chok AKL, Ting Ang ZL, et al. Impact of free cancer predisposition cascade genetic testing
on uptake in Singapore. NPJ Genom Med 2019;4(1):22. https://doi.org/10.1038/s41525-019-0096-5
56. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening
decisions. JAMA 2014;311(13):1327. https://doi.org/10.1001/jama.2014.1398
57. Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic
counseling, and genetic testing for BRCA-related cancer in women: A systematic review to update the
U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2014;160(4):255-266. https://
doi.org/10.7326/M13-1684
Downloads
Published
Issue
Section
License
Copyright (c) 2026 S Barnard, B Rossouw, E Gilfillan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
